The Experts below are selected from a list of 93 Experts worldwide ranked by ideXlab platform
Nobuhiro Ohkohchi - One of the best experts on this subject based on the ideXlab platform.
-
Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer.
Pancreas, 2020Co-Authors: Ryoichi Miyamoto, Shinji Hashimoto, Tomohiro Kurokawa, Keisuke Kohno, Yoshimasa Akashi, Yusuke Ohara, Keiichi Yamada, Tsuyoshi Enomoto, Nobuhiro OhkohchiAbstract:OBJECTIVE: Thrombocytosis in patients with various cancers has been considered a parameter for poor prognosis; however, its contribution to pancreatic cancer remains controversial. METHODS: Potential preoperative prognostic parameters (platelets, neutrophils, lymphocytes, the platelet-lymphocyte ratio, the neutrophil-lymphocyte ratio, the serum C-reactive protein [CRP], and carbohydrate antigen 19-9) were retrospectively analyzed in 95 patients with pancreatic cancer. Cutoff Values were defined according to receiver operating characteristic curve analysis, and median survival times (MSTs) were compared. RESULTS: Median survival times (days) significantly differed according to platelet count (high [552] vs low [735], P = 0.017), CRP (high [471] vs low [750], P = 0.001), and carbohydrate antigen 19-9 level (high [639] vs low [765], P = 0.021), whereas there was no difference in the platelet-lymphocyte ratio and the neutrophil-lymphocyte ratio. Multivariate analysis identified thrombocytosis (hazard ratio, 2.015) and CRP level (hazard ratio, 1.771) as independent prognostic factors. The combinatory effects of platelets and the inflammatory response using a platelet × CRP Multiplier Value could effectively distinguished the MSTs (days) of patients with pancreatic cancer (high [482] vs low [812], P < 0.001). CONCLUSIONS: Thrombocytosis and CRP influenced pancreatic cancer patient prognosis. Platelet × CRP Multiplier is assumed as a useful parameter that reflects the contribution of activated platelets to cancer progression.
-
platelet crp Multiplier Value as an indicator of poor prognosis in patients with resectable pancreatic cancer
Pancreas, 2017Co-Authors: Ryoichi Miyamoto, Shinji Hashimoto, Tomohiro Kurokawa, Keisuke Kohno, Yoshimasa Akashi, Yusuke Ohara, Keiichi Yamada, Tsuyoshi Enomoto, Nobuhiro OhkohchiAbstract:OBJECTIVE: Thrombocytosis in patients with various cancers has been considered a parameter for poor prognosis; however, its contribution to pancreatic cancer remains controversial. METHODS: Potential preoperative prognostic parameters (platelets, neutrophils, lymphocytes, the platelet-lymphocyte ratio, the neutrophil-lymphocyte ratio, the serum C-reactive protein [CRP], and carbohydrate antigen 19-9) were retrospectively analyzed in 95 patients with pancreatic cancer. Cutoff Values were defined according to receiver operating characteristic curve analysis, and median survival times (MSTs) were compared. RESULTS: Median survival times (days) significantly differed according to platelet count (high [552] vs low [735], P = 0.017), CRP (high [471] vs low [750], P = 0.001), and carbohydrate antigen 19-9 level (high [639] vs low [765], P = 0.021), whereas there was no difference in the platelet-lymphocyte ratio and the neutrophil-lymphocyte ratio. Multivariate analysis identified thrombocytosis (hazard ratio, 2.015) and CRP level (hazard ratio, 1.771) as independent prognostic factors. The combinatory effects of platelets and the inflammatory response using a platelet × CRP Multiplier Value could effectively distinguished the MSTs (days) of patients with pancreatic cancer (high [482] vs low [812], P < 0.001). CONCLUSIONS: Thrombocytosis and CRP influenced pancreatic cancer patient prognosis. Platelet × CRP Multiplier is assumed as a useful parameter that reflects the contribution of activated platelets to cancer progression.
Ryoichi Miyamoto - One of the best experts on this subject based on the ideXlab platform.
-
Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer.
Pancreas, 2020Co-Authors: Ryoichi Miyamoto, Shinji Hashimoto, Tomohiro Kurokawa, Keisuke Kohno, Yoshimasa Akashi, Yusuke Ohara, Keiichi Yamada, Tsuyoshi Enomoto, Nobuhiro OhkohchiAbstract:OBJECTIVE: Thrombocytosis in patients with various cancers has been considered a parameter for poor prognosis; however, its contribution to pancreatic cancer remains controversial. METHODS: Potential preoperative prognostic parameters (platelets, neutrophils, lymphocytes, the platelet-lymphocyte ratio, the neutrophil-lymphocyte ratio, the serum C-reactive protein [CRP], and carbohydrate antigen 19-9) were retrospectively analyzed in 95 patients with pancreatic cancer. Cutoff Values were defined according to receiver operating characteristic curve analysis, and median survival times (MSTs) were compared. RESULTS: Median survival times (days) significantly differed according to platelet count (high [552] vs low [735], P = 0.017), CRP (high [471] vs low [750], P = 0.001), and carbohydrate antigen 19-9 level (high [639] vs low [765], P = 0.021), whereas there was no difference in the platelet-lymphocyte ratio and the neutrophil-lymphocyte ratio. Multivariate analysis identified thrombocytosis (hazard ratio, 2.015) and CRP level (hazard ratio, 1.771) as independent prognostic factors. The combinatory effects of platelets and the inflammatory response using a platelet × CRP Multiplier Value could effectively distinguished the MSTs (days) of patients with pancreatic cancer (high [482] vs low [812], P < 0.001). CONCLUSIONS: Thrombocytosis and CRP influenced pancreatic cancer patient prognosis. Platelet × CRP Multiplier is assumed as a useful parameter that reflects the contribution of activated platelets to cancer progression.
-
platelet crp Multiplier Value as an indicator of poor prognosis in patients with resectable pancreatic cancer
Pancreas, 2017Co-Authors: Ryoichi Miyamoto, Shinji Hashimoto, Tomohiro Kurokawa, Keisuke Kohno, Yoshimasa Akashi, Yusuke Ohara, Keiichi Yamada, Tsuyoshi Enomoto, Nobuhiro OhkohchiAbstract:OBJECTIVE: Thrombocytosis in patients with various cancers has been considered a parameter for poor prognosis; however, its contribution to pancreatic cancer remains controversial. METHODS: Potential preoperative prognostic parameters (platelets, neutrophils, lymphocytes, the platelet-lymphocyte ratio, the neutrophil-lymphocyte ratio, the serum C-reactive protein [CRP], and carbohydrate antigen 19-9) were retrospectively analyzed in 95 patients with pancreatic cancer. Cutoff Values were defined according to receiver operating characteristic curve analysis, and median survival times (MSTs) were compared. RESULTS: Median survival times (days) significantly differed according to platelet count (high [552] vs low [735], P = 0.017), CRP (high [471] vs low [750], P = 0.001), and carbohydrate antigen 19-9 level (high [639] vs low [765], P = 0.021), whereas there was no difference in the platelet-lymphocyte ratio and the neutrophil-lymphocyte ratio. Multivariate analysis identified thrombocytosis (hazard ratio, 2.015) and CRP level (hazard ratio, 1.771) as independent prognostic factors. The combinatory effects of platelets and the inflammatory response using a platelet × CRP Multiplier Value could effectively distinguished the MSTs (days) of patients with pancreatic cancer (high [482] vs low [812], P < 0.001). CONCLUSIONS: Thrombocytosis and CRP influenced pancreatic cancer patient prognosis. Platelet × CRP Multiplier is assumed as a useful parameter that reflects the contribution of activated platelets to cancer progression.
Philip H. W. Leong - One of the best experts on this subject based on the ideXlab platform.
-
A Two-Speed, Radix-4, Serial–Parallel Multiplier
IEEE Transactions on Very Large Scale Integration Systems, 2019Co-Authors: Duncan J. M. Moss, David Boland, Philip H. W. LeongAbstract:In this paper, we present a two-speed, radix-4, serial-parallel Multiplier for accelerating applications such as digital filters, artificial neural networks, and other machine learning algorithms. Our Multiplier is a variant of the serial–parallel (SP) modified radix-4 Booth Multiplier that adds only the nonzero Booth encodings and skips over the zero operations, making the latency dependent on the Multiplier Value. Two subcircuits with different critical paths are utilized so that throughput and latency are improved for a subset of Multiplier Values. The Multiplier is evaluated on an Intel Cyclone V field-programmable gate array against standard parallel–parallel and SP Multipliers across four different process–voltage–temperature corners. We show that for bit widths of 32 and 64, our optimizations can result in a $1.42\times $ – $3.36\times $ improvement over the standard parallel Booth Multiplier in terms of area–time depending on the input set.
-
A Two-Speed, Radix-4, Serial–Parallel Multiplier
IEEE Transactions on Very Large Scale Integration (VLSI) Systems, 2019Co-Authors: Duncan J. M. Moss, David Boland, Philip H. W. LeongAbstract:In this paper, we present a two-speed, radix-4, serial-parallel Multiplier for accelerating applications such as digital filters, artificial neural networks, and other machine learning algorithms. Our Multiplier is a variant of the serial-parallel (SP) modified radix-4 Booth Multiplier that adds only the nonzero Booth encodings and skips over the zero operations, making the latency dependent on the Multiplier Value. Two subcircuits with different critical paths are utilized so that throughput and latency are improved for a subset of Multiplier Values. The Multiplier is evaluated on an Intel Cyclone V field-programmable gate array against standard parallel-parallel and SP Multipliers across four different process-voltage-temperature corners. We show that for bit widths of 32 and 64, our optimizations can result in a 1.42×-$3.36× improvement over the standard parallel Booth Multiplier in terms of area-time depending on the input set.
Tomohiro Kurokawa - One of the best experts on this subject based on the ideXlab platform.
-
Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer.
Pancreas, 2020Co-Authors: Ryoichi Miyamoto, Shinji Hashimoto, Tomohiro Kurokawa, Keisuke Kohno, Yoshimasa Akashi, Yusuke Ohara, Keiichi Yamada, Tsuyoshi Enomoto, Nobuhiro OhkohchiAbstract:OBJECTIVE: Thrombocytosis in patients with various cancers has been considered a parameter for poor prognosis; however, its contribution to pancreatic cancer remains controversial. METHODS: Potential preoperative prognostic parameters (platelets, neutrophils, lymphocytes, the platelet-lymphocyte ratio, the neutrophil-lymphocyte ratio, the serum C-reactive protein [CRP], and carbohydrate antigen 19-9) were retrospectively analyzed in 95 patients with pancreatic cancer. Cutoff Values were defined according to receiver operating characteristic curve analysis, and median survival times (MSTs) were compared. RESULTS: Median survival times (days) significantly differed according to platelet count (high [552] vs low [735], P = 0.017), CRP (high [471] vs low [750], P = 0.001), and carbohydrate antigen 19-9 level (high [639] vs low [765], P = 0.021), whereas there was no difference in the platelet-lymphocyte ratio and the neutrophil-lymphocyte ratio. Multivariate analysis identified thrombocytosis (hazard ratio, 2.015) and CRP level (hazard ratio, 1.771) as independent prognostic factors. The combinatory effects of platelets and the inflammatory response using a platelet × CRP Multiplier Value could effectively distinguished the MSTs (days) of patients with pancreatic cancer (high [482] vs low [812], P < 0.001). CONCLUSIONS: Thrombocytosis and CRP influenced pancreatic cancer patient prognosis. Platelet × CRP Multiplier is assumed as a useful parameter that reflects the contribution of activated platelets to cancer progression.
-
platelet crp Multiplier Value as an indicator of poor prognosis in patients with resectable pancreatic cancer
Pancreas, 2017Co-Authors: Ryoichi Miyamoto, Shinji Hashimoto, Tomohiro Kurokawa, Keisuke Kohno, Yoshimasa Akashi, Yusuke Ohara, Keiichi Yamada, Tsuyoshi Enomoto, Nobuhiro OhkohchiAbstract:OBJECTIVE: Thrombocytosis in patients with various cancers has been considered a parameter for poor prognosis; however, its contribution to pancreatic cancer remains controversial. METHODS: Potential preoperative prognostic parameters (platelets, neutrophils, lymphocytes, the platelet-lymphocyte ratio, the neutrophil-lymphocyte ratio, the serum C-reactive protein [CRP], and carbohydrate antigen 19-9) were retrospectively analyzed in 95 patients with pancreatic cancer. Cutoff Values were defined according to receiver operating characteristic curve analysis, and median survival times (MSTs) were compared. RESULTS: Median survival times (days) significantly differed according to platelet count (high [552] vs low [735], P = 0.017), CRP (high [471] vs low [750], P = 0.001), and carbohydrate antigen 19-9 level (high [639] vs low [765], P = 0.021), whereas there was no difference in the platelet-lymphocyte ratio and the neutrophil-lymphocyte ratio. Multivariate analysis identified thrombocytosis (hazard ratio, 2.015) and CRP level (hazard ratio, 1.771) as independent prognostic factors. The combinatory effects of platelets and the inflammatory response using a platelet × CRP Multiplier Value could effectively distinguished the MSTs (days) of patients with pancreatic cancer (high [482] vs low [812], P < 0.001). CONCLUSIONS: Thrombocytosis and CRP influenced pancreatic cancer patient prognosis. Platelet × CRP Multiplier is assumed as a useful parameter that reflects the contribution of activated platelets to cancer progression.
Keisuke Kohno - One of the best experts on this subject based on the ideXlab platform.
-
Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer.
Pancreas, 2020Co-Authors: Ryoichi Miyamoto, Shinji Hashimoto, Tomohiro Kurokawa, Keisuke Kohno, Yoshimasa Akashi, Yusuke Ohara, Keiichi Yamada, Tsuyoshi Enomoto, Nobuhiro OhkohchiAbstract:OBJECTIVE: Thrombocytosis in patients with various cancers has been considered a parameter for poor prognosis; however, its contribution to pancreatic cancer remains controversial. METHODS: Potential preoperative prognostic parameters (platelets, neutrophils, lymphocytes, the platelet-lymphocyte ratio, the neutrophil-lymphocyte ratio, the serum C-reactive protein [CRP], and carbohydrate antigen 19-9) were retrospectively analyzed in 95 patients with pancreatic cancer. Cutoff Values were defined according to receiver operating characteristic curve analysis, and median survival times (MSTs) were compared. RESULTS: Median survival times (days) significantly differed according to platelet count (high [552] vs low [735], P = 0.017), CRP (high [471] vs low [750], P = 0.001), and carbohydrate antigen 19-9 level (high [639] vs low [765], P = 0.021), whereas there was no difference in the platelet-lymphocyte ratio and the neutrophil-lymphocyte ratio. Multivariate analysis identified thrombocytosis (hazard ratio, 2.015) and CRP level (hazard ratio, 1.771) as independent prognostic factors. The combinatory effects of platelets and the inflammatory response using a platelet × CRP Multiplier Value could effectively distinguished the MSTs (days) of patients with pancreatic cancer (high [482] vs low [812], P < 0.001). CONCLUSIONS: Thrombocytosis and CRP influenced pancreatic cancer patient prognosis. Platelet × CRP Multiplier is assumed as a useful parameter that reflects the contribution of activated platelets to cancer progression.
-
platelet crp Multiplier Value as an indicator of poor prognosis in patients with resectable pancreatic cancer
Pancreas, 2017Co-Authors: Ryoichi Miyamoto, Shinji Hashimoto, Tomohiro Kurokawa, Keisuke Kohno, Yoshimasa Akashi, Yusuke Ohara, Keiichi Yamada, Tsuyoshi Enomoto, Nobuhiro OhkohchiAbstract:OBJECTIVE: Thrombocytosis in patients with various cancers has been considered a parameter for poor prognosis; however, its contribution to pancreatic cancer remains controversial. METHODS: Potential preoperative prognostic parameters (platelets, neutrophils, lymphocytes, the platelet-lymphocyte ratio, the neutrophil-lymphocyte ratio, the serum C-reactive protein [CRP], and carbohydrate antigen 19-9) were retrospectively analyzed in 95 patients with pancreatic cancer. Cutoff Values were defined according to receiver operating characteristic curve analysis, and median survival times (MSTs) were compared. RESULTS: Median survival times (days) significantly differed according to platelet count (high [552] vs low [735], P = 0.017), CRP (high [471] vs low [750], P = 0.001), and carbohydrate antigen 19-9 level (high [639] vs low [765], P = 0.021), whereas there was no difference in the platelet-lymphocyte ratio and the neutrophil-lymphocyte ratio. Multivariate analysis identified thrombocytosis (hazard ratio, 2.015) and CRP level (hazard ratio, 1.771) as independent prognostic factors. The combinatory effects of platelets and the inflammatory response using a platelet × CRP Multiplier Value could effectively distinguished the MSTs (days) of patients with pancreatic cancer (high [482] vs low [812], P < 0.001). CONCLUSIONS: Thrombocytosis and CRP influenced pancreatic cancer patient prognosis. Platelet × CRP Multiplier is assumed as a useful parameter that reflects the contribution of activated platelets to cancer progression.
